Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Bionovo Announces Second Quarter 2011 Highlights and Financial Results

August 3, 2011 By Bio-Medicine.Org

EMERYVILLE, Calif., Aug. 3, 2011 /PRNewswire/ — Bionovo, Inc.
(NASDAQ:
BNVI) today announced second quarter highlights and financial
results for the three months ended June 30, 2011.

“We have made excellent progress on our menopausal hot flash
drug candidate, MF101, or Menerba™, during the past quarter,
delivering on milestones and commitments,” said Isaac Cohen,
O.M.D., Bionovo’s Chairman and Chief Executive Officer. “We have
completed the tasks which were required for us to begin the phase 3
clinical trial for Menerba, and we are on track to initiate the
trial in the third quarter.”

Key Events and Milestones

The Company successfully completed non-clinical toxicology studies
of Menerba in two animal species.  As expected no serious
adverse events or toxicities were observed in these studies. The
drug was well tolerated by the animals. The Company successfully
completed a 28-day tolerability trial of Menerba in women,
investigating higher doses. As expected, there were no safety
concerns, no reports of serious adverse events, no changes to blood
pressure, heart rate or lab values and no cases of abnormal uterine
findings on endometrial biopsies.  A dosing strategy has been
established for the phase 3 study. The Company completed the
manufacture of the requisite ten batches for the phase 3 clinical
trial of Menerba, and is preparing the submission of data to the
FDA. The Company has identified, selected, and is working with
personnel at 45 initial clinical trial sites for the phase 3
clinical trial of Menerba. The Company also published further
information on the mechanism of action of its breast cancer drug
candidate, Bezielle™, as well as further information on novel
approaches for the quantification of actives in botanical drug
mixtures. The Company presented data from the Phase 2

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech